IQ-AI Limited IB Software Chosen for Accuracy and Automation (0638M)
17 Septiembre 2021 - 12:59AM
UK Regulatory
TIDMIQAI
RNS Number : 0638M
IQ-AI Limited
17 September 2021
17 September 2021
IQ-AI Limited
("IQ-AI" or the "Company")
IB Software Chosen for Quantitative Accuracy and Automation
IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF) today announced the
sale of multiple licenses of Imaging Biometrics (IB) software for
the automated generation of quantitative perfusion maps. The sales
consist of renewal licenses for established clients and a new
installation of IB Clinic at the Eastern Alabama Medical Center
(EAMC).
IB Clinic - Container edition is a fully automated processing
pipeline for all IB Software modules, including IB Neuro, IB Delta
T1 maps, IB DCE, and IB Diffusion. Ever since it has been made
available, the clinical adoption of the container edition has grown
steadily with hospitals and imaging centers of all sizes. Of value
to clinicians is the automated generation of IB's quantitative
output maps and, specifically, IB Neuro's quantitative relative
cerebral blood volume (rCBV) maps; a magnetic resonance imaging
(MRI) method for evaluating brain tumors. The automated workflow
frees valuable resources, such as neuro radiologists and MR
Technologists while, at the same time, provides unique information
shown useful in the diagnosis and treatment optimization of brain
tumor patients.
It is the quantitative capabilities of IB software that allows
for a standardized imaging protocol across sites and platforms. For
instance, a patient scanned at one site on a given MR scanner
platform can have a follow-up scan performed on a different MR
scanner and the data, if processed with IB Neuro, will be directly
comparable and enable accurate longitudinal assessment.
Quantitatively assessing how a tumor is changing over time is
critical for both clinicians and their patients.
Added Dr. Matthew Dobbs, MD, a radiologist at EAMC, "We have
been using IB quantitative perfusion imaging for over a year at our
main cancer center and the information has been invaluable to us in
determining brain tumor treatment planning and follow-up. When the
radiation oncologists at one of our hospitals requested MR
perfusion, we immediately recommended purchasing IB software based
on our positive experiences."
"While the pandemic negatively impacted sales earlier this year,
we are grateful for the rapid return of sales activity as well as
trial evaluations of our software," said Michael Schmainda, CEO of
IB.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda
Tel: 020 7469 0930
-----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
-----------------------------------------------------------
About Imaging Biometrics, LLC
Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI)
(OTCQB: IQAIF), develops and provides visualisation and analytical
solutions that enable clinicians to better diagnose and treat
disease with greater confidence. Through close collaboration with
top researchers and clinicians, sophisticated advancements are
translated into platform-independent and automated software
plug-ins which can extend the base functionality of workstations,
imaging systems, PACS, or medical viewers. By design, IB's advanced
visualisation software seamlessly integrates into routine
workflows. For more information about Imaging Biometrics, visit the
company's website at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDEASNKFSAFEFA
(END) Dow Jones Newswires
September 17, 2021 01:59 ET (05:59 GMT)
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024